Long Non-coding RNA: A Key Regulator in the Pathogenesis of Diabetic Cardiomyopathy

Guo, Yaoyao; Feng, Xiaohui; Wang, Dan; Kang, Xiaonan; Zhang, Lu; Ren, Huihui; Yuan, Gang

doi:10.3389/fcvm.2021.655598

Cited by 12 publications

(11 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The involvement of histone methylation in controlling gene expression in DCM by modulating cytokine production, gap junction integrity, mitochondrial dysfunction, metabolic imbalance, cardiac cell death and tissue inflammation is certain [ 84 , 85 , 86 ]. Along with transcriptional regulation, the role of long non-coding RNAs and micro-RNAs in the modulation of cardiac protein expression in DCM is a topic of great interest [ 87 , 88 , 89 , 90 ]. Epigenetic mechanisms act in different regulatory pathways in order to control gene expression.…”

Section: Epigenetic Involvement In Diabetic Cardiomyopathymentioning

confidence: 99%

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Gonçalves

Vasques

et al. 2022

Cells

View full text Add to dashboard Cite

The incidence and prevalence of diabetes mellitus (DM) are increasing worldwide, and the resulting cardiac complications are the leading cause of death. Among these complications is diabetes-induced cardiomyopathy (DCM), which is the consequence of a pro-inflammatory condition, oxidative stress and fibrosis caused by hyperglycemia. Cardiac remodeling will lead to an imbalance in cell survival and death, which can promote cardiac dysfunction. Since the conventional treatment of DM generally does not address the prevention of cardiac remodeling, it is important to develop new alternatives for the treatment of cardiovascular complications induced by DM. Thus, therapy with mesenchymal stem cells has been shown to be a promising approach for the prevention of DCM because of their anti-apoptotic, anti-fibrotic and anti-inflammatory effects, which could improve cardiac function in patients with DM.

show abstract

Section: Epigenetic Involvement In Diabetic Cardiomyopathymentioning

confidence: 99%

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Gonçalves

Vasques

et al. 2022

Cells

View full text Add to dashboard Cite

show abstract

“…Apart from miRNAs, different lncRNAs got isolated that were implicated in the modulation of cardiac cell demise in hyperglycemic or diabetic situations [61]. Reduction in the expression of lncRNAs H19 in hyperglycemiatreated cardiomyocytes was seen along with enhanced ventricular function in diabetic mice by impeding reduced apoptosis [62].…”

Section: Epigenetics Controlling Of Apoptosismentioning

confidence: 99%

Diabetic Cardiomyopathy: An Update on Its Pathophysiology With Specific Emphasis on Epigenetics Modifications Besides Treatment – A Systematic Review

Kulvinder¹,

Nand²,

Singh³

2023

BIJRDPM

View full text Add to dashboard Cite

Diabetes mellitus (DM) represents a signiﬁcant lifestyle disease. Of the types of DM, type 2 DM aids maximuminthedevelopmentofcardiovasculardisease(CVD)alongwithdiabeticcardiomyopathy(DbCM),which iscorrelatedwithsigniﬁcantmortalityalongwithcomorbidityindiabeticpatients.DbCMisanon-canonicalcardiac illness that exhibits cardiac remodelling occurs when there is DM but not when there is any concomitant conditions like hypertension, valve disease, or coronary artery disease (CAD). DbCM is linked to altered mitochondrial structure and function, as well as aberrant cardiac metabolism. Additional physiological and pathological signaling mechanisms include inﬂammation, oxidative stress (OS), and others; besides, in the diabetic environment, there are various cardiomyopathy-inducing factors such as reactive oxygen species (ROS)-modulated OS, hyperglycemic situations, cytokines-modulated These mediators induce inﬂammatory responses, cell death, including apoptosis, pyroptosis,andautophagy,aswellastheepigeneticcontrolofabnormalmolecularpathways.Thelasttenyearshave demonstrated the importance of miRNAs and long noncoding RNAs (lncRNAs) in controlling key biological processessuchcelldeath,mitochondrialdysfunction,andelectricalremodelling.Cardiomyopathyisasigniﬁcantevent regardingcardiacremodelingeventinDbCM.Considerableproofexistsregardingthepartofepigeneticsindiabetic correlated cell demise. Epigenetic controlling modes like histone alterations, DNA methylation, and miRNA along with lncRNAs control cardiac cell demise in the diabetic environment. Akin to that, other modes such as mitochondrialimpairmentandOSarecontrolledbymiRNAalongwithlncRNAs.Findingthesemodeshasgivenprovisionof generationofinnovativetherapyapproachesforDbCM.miRNAsalongwithlncRNAshaveillustratedtranslational capacity in the form of Besides treatment options, There are other DbCM-speciﬁc diagnostic and prognostic biomarkers available. HDACs were further shown to have a crucial role in controlling the pathogenesis of DbCM.

show abstract

“… 275 Other lncRNAs that have been implicated in the pathogenesis of diabetic cardiomyopathy include HOTAIR, 277 MALAT1, 278 MIAT, 279 , 280 CRNDE, 281 and TUG1, 282 among others. 269 , 274 In regard to circRNAs, up-regulation of circRNA_000203 has been found in diabetic mouse myocardium and was associated with increased expression of pro-fibrotic genes in cardiac fibroblasts. 283 Similarly, circRNA_010567 expression was found to be up-regulated in murine diabetic myocardium and implicated in myocardial fibrosis by sponging miR-141, which directly targets pro-fibrotic TGF-β1.…”

Section: Extracellular Vesicles Mediate Cellular and Tissue Crosstalkmentioning

confidence: 99%

Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy

Phang

Ritchie

Hausenloy

et al. 2022

Cardiovascular Research

View full text Add to dashboard Cite

Patients with Type 2 diabetes mellitus (T2DM) frequently exhibit a distinctive cardiac phenotype known as diabetic cardiomyopathy. Cardiac complications associated with T2DM include cardiac inflammation, hypertrophy, fibrosis and diastolic dysfunction in the early stages of the disease, which can progress to systolic dysfunction and heart failure. Effective therapeutic options for diabetic cardiomyopathy are limited and often have conflicting results. The lack of effective treatments for diabetic cardiomyopathy is due in part, to our poor understanding of the disease development and progression, as well as a lack of robust and valid preclinical human models that can accurately recapitulate the pathophysiology of the human heart. In addition to cardiomyocytes, the heart contains a heterogeneous population of non-myocytes including fibroblasts, vascular cells, autonomic neurons and immune cells. These cardiac non-myocytes play important roles in cardiac homeostasis and disease, yet the effect of hyperglycaemia and hyperlipidaemia on these cell types are often overlooked in preclinical models of diabetic cardiomyopathy. The advent of human induced pluripotent stem cells provides a new paradigm in which to model diabetic cardiomyopathy as they can be differentiated into all cell types in the human heart. This review will discuss the roles of cardiac non-myocytes and their dynamic intercellular interactions in the pathogenesis of diabetic cardiomyopathy. We will also discuss the use of sodium-glucose cotransporter 2 inhibitors as a therapy for diabetic cardiomyopathy and their known impacts on non-myocytes. These developments will no doubt facilitate the discovery of novel treatment targets for preventing the onset and progression of diabetic cardiomyopathy.

show abstract

Long Non-coding RNA: A Key Regulator in the Pathogenesis of Diabetic Cardiomyopathy

Cited by 12 publications

References 67 publications

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Mesenchymal Stem Cell Therapy in Diabetic Cardiomyopathy

Diabetic Cardiomyopathy: An Update on Its Pathophysiology With Specific Emphasis on Epigenetics Modifications Besides Treatment – A Systematic Review

Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy

Contact Info

Product

Resources

About